DE69711519T2 - Carbazolanaloge als selektive beta3-adrenergische Agonisten - Google Patents

Carbazolanaloge als selektive beta3-adrenergische Agonisten

Info

Publication number
DE69711519T2
DE69711519T2 DE69711519T DE69711519T DE69711519T2 DE 69711519 T2 DE69711519 T2 DE 69711519T2 DE 69711519 T DE69711519 T DE 69711519T DE 69711519 T DE69711519 T DE 69711519T DE 69711519 T2 DE69711519 T2 DE 69711519T2
Authority
DE
Germany
Prior art keywords
alkyl
hydrogen
optionally substituted
mmol
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69711519T
Other languages
German (de)
English (en)
Other versions
DE69711519D1 (de
Inventor
Thomas Alan Crowell
Deborah Ann Evrard
Charles David Jones
Brian Stephen Muehl
Christopher John Rito
Anthony John Shuker
Andrew John Thorpe
Kenneth Jeff Thrasher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69711519D1 publication Critical patent/DE69711519D1/de
Application granted granted Critical
Publication of DE69711519T2 publication Critical patent/DE69711519T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69711519T 1996-09-05 1997-08-27 Carbazolanaloge als selektive beta3-adrenergische Agonisten Expired - Lifetime DE69711519T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2581896P 1996-09-05 1996-09-05
US2922896P 1996-10-30 1996-10-30

Publications (2)

Publication Number Publication Date
DE69711519D1 DE69711519D1 (de) 2002-05-08
DE69711519T2 true DE69711519T2 (de) 2002-10-31

Family

ID=26700197

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69711519T Expired - Lifetime DE69711519T2 (de) 1996-09-05 1997-08-27 Carbazolanaloge als selektive beta3-adrenergische Agonisten

Country Status (13)

Country Link
US (4) US6140352A (enExample)
EP (1) EP0827746B1 (enExample)
JP (1) JP4212117B2 (enExample)
AR (2) AR009519A1 (enExample)
AT (1) ATE215369T1 (enExample)
AU (1) AU4094197A (enExample)
CO (1) CO4910132A1 (enExample)
DE (1) DE69711519T2 (enExample)
ES (1) ES2171839T3 (enExample)
ID (1) ID17182A (enExample)
MY (1) MY132626A (enExample)
PE (1) PE109398A1 (enExample)
WO (1) WO1998009625A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE215369T1 (de) * 1996-09-05 2002-04-15 Lilly Co Eli Carbazolanaloge als selektive beta3-adrenergische agonisten
CO5011072A1 (es) * 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
US6232337B1 (en) * 1997-12-05 2001-05-15 Eli Lilly And Company Selective β3 adrenergic agonists
CA2355079A1 (en) * 1998-12-15 2000-06-22 Shiro Miyoshi Novel heterocyclic compounds and drug compositions containing the same
AU6050000A (en) * 1999-07-22 2001-02-13 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
AU6049500A (en) * 1999-07-22 2001-02-13 Eli Lilly And Company Treatment of cardiac abnormalities with aryloxy propanolamines
MXPA02004653A (es) * 1999-11-15 2002-09-02 Lilly Co Eli Ariloxipropanolaminas para mejorar la produccion de ganado.
AU1572701A (en) * 1999-11-15 2001-05-30 Eli Lilly And Company Treating wasting syndromes with aryloxy propanolamines
US6841563B1 (en) 1999-11-15 2005-01-11 Eli Lilly And Company Aryloxy propanolamines for improving livestock production
AU1580001A (en) * 1999-11-15 2001-05-30 Eli Lilly And Company Process for the preparation of aryloxy propanolamines
JP2003520226A (ja) 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
AUPQ585000A0 (en) * 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
EP1134221A1 (en) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
JP5000828B2 (ja) * 2000-03-15 2012-08-15 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ＩｋＢキナーゼ阻害活性を有する置換ベーターカルボリン
CA2415331A1 (en) 2000-07-13 2002-01-24 Eli Lilly And Company Beta3 adrenergic agonists
US6537994B2 (en) * 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
DE60120748T2 (de) 2000-11-10 2007-05-16 Eli Lilly And Co., Indianapolis 3-substituierte oxindolderivate als beta-3-agonisten
KR100408122B1 (ko) * 2000-12-08 2003-12-01 한국디디에스제약 주식회사 광학 입체 이성질체의 성질을 갖는 베타 아드레날린 길항제의 제조 방법
JP2005507872A (ja) 2001-08-14 2005-03-24 イーライ・リリー・アンド・カンパニー ３−置換オキシインドールβ３アゴニスト
ES2272749T3 (es) 2001-08-14 2007-05-01 Eli Lilly And Company Derivados de indol como agonistas beta-3 adrenergicos para el tratamiento de diabetes tipo 2.
ES2299618T3 (es) 2001-11-20 2008-06-01 Eli Lilly And Company Agonistas beta-3-adrenergicos.
EP1448560B1 (en) 2001-11-20 2005-06-15 Eli Lilly And Company 3-SUBSTITUTED OXINDOLE beta 3 AGONISTS
AU2002357084A1 (en) 2002-01-11 2003-07-30 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists
UA80437C2 (en) * 2002-09-19 2007-09-25 Lilly Co Eli Diaryl ethers as opioid receptor antagonist
CA2518194A1 (en) 2003-03-07 2004-09-23 Eli Lilly And Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
JP3751312B2 (ja) * 2003-04-23 2006-03-01 日本たばこ産業株式会社 ＣａＳＲアンタゴニスト
US7375100B2 (en) 2003-06-04 2008-05-20 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
US7196100B2 (en) 2003-12-12 2007-03-27 Eli Lilly And Company Opioid receptor antagonists
EP1699783B1 (en) * 2003-12-22 2012-07-25 Eli Lilly And Company Opioid receptor antagonists
WO2005080329A2 (en) 2004-02-23 2005-09-01 Cadila Healthcar Limited Process for manufacture of racemic carvedilol
AU2005275185B2 (en) 2004-07-22 2011-06-23 Eli Lilly And Company A crystalline variable hydrate of (S)-6-(4-(2-((3-(9H-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt
ES2265276B1 (es) * 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
RS53155B2 (sr) 2005-09-14 2021-10-29 Takeda Pharmaceuticals Co Administracija inhibitora dipeptidil peptidaze
ZA200803226B (en) * 2005-10-13 2009-11-25 Orchid Res Lab Ltd Heterocyclic Compounds as Pstat3/IL-6 Inhibitors
WO2007077111A1 (en) * 2005-12-30 2007-07-12 F. Hoffmann-La Roche Ag Compounds and methods for carbazole synthesis
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
KR20090051778A (ko) 2006-09-08 2009-05-22 화이자 프로덕츠 인코포레이티드 다이아릴 에터 유도체 및 이의 용도
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
PE20120991A1 (es) * 2009-09-18 2012-08-01 Adolor Corp Antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
EP2515890A4 (en) 2009-12-21 2013-07-17 Univ Queensland NEURAL STIMULATION
PT2531501E (pt) 2010-02-03 2014-02-17 Takeda Pharmaceutical Inibidores da cinase de regulação do sinal de apoptose 1
CN103476593B (zh) * 2011-01-20 2016-02-24 录象射流技术公司 用于测量色带张力的系统
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
WO2013169597A1 (en) * 2012-05-08 2013-11-14 Dow Agrosciences Llc Substituted 1,2,4-triazole compounds as a seed treatment to control pests
ES2394349B1 (es) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
BR112015006230A2 (pt) 2012-10-02 2017-07-04 Lilly Co Eli métodos para aprimorar produção de galinha
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP4049665B1 (en) 2016-03-15 2025-03-12 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US10865163B2 (en) 2017-12-20 2020-12-15 The University Of Toledo Carbon dioxide as a directing group for C—H functionalization reactions involving Lewis basic amines, alcohols, thiols, and phosphines for the synthesis of compounds
CN110668994A (zh) * 2019-11-12 2020-01-10 山东创新药物研发有限公司 左旋卡维地洛盐晶型、其制备方法及应用
CN115611752A (zh) * 2022-10-21 2023-01-17 江苏天和制药有限公司 一种卢巴贝隆中间体的合成精制方法

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2516E (fr) 1903-08-17 1904-04-27 Joseph Henri Desgeorge Perfectionnement aux appareils photographiques
SE379196B (enExample) * 1971-06-24 1975-09-29 Sandoz Ag
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPS5310974B2 (enExample) * 1974-06-10 1978-04-18
CH624395A5 (enExample) * 1976-01-08 1981-07-31 Ciba Geigy Ag
DE2609645A1 (de) * 1976-03-09 1977-09-15 Boehringer Sohn Ingelheim Aminoalkylheterocyclen
DE2645710C2 (de) * 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
DE2830211A1 (de) * 1977-07-21 1979-02-01 Sandoz Ag Substituierte indol-derivate, ihre herstellung und verwendung
US4235919A (en) * 1977-07-21 1980-11-25 Sandoz Ltd. 1-(Indol-4-yloxy)-3-(2-substituted amino)-2-propanols and pharmaceutical use thereof
CA1108619A (en) * 1977-08-12 1981-09-08 Carl H. Ross 4-hydroxy-2-benzimidazolinone derivatives and the preparation thereof
DE2805404A1 (de) * 1978-02-09 1979-08-16 Merck Patent Gmbh 1-aryloxy-3-nitratoalkylamino-2-propanole und verfahren zu ihrer herstellung
DE2965655D1 (en) * 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
US4391826A (en) * 1978-07-03 1983-07-05 Eli Lilly And Company Phenethanolamines, compositions containing the same, and method for effecting weight control
CH636856A5 (en) * 1978-07-17 1983-06-30 Sandoz Ag 4-(3-Aminopropoxy)indole derivatives, their preparation and medicines containing them
US4751246A (en) * 1978-08-30 1988-06-14 Sterling Drug Inc. Compositions and method
DE2905877A1 (de) * 1979-02-16 1980-08-28 Boehringer Mannheim Gmbh Neue aminopropanolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DD150456A5 (de) * 1979-03-01 1981-09-02 Ciba Geigy Ag Verfahren zur herstellung von derivaten des 3-amino-1,2-propandiols
EP0023385B1 (en) * 1979-06-16 1982-12-15 Beecham Group Plc Ethanamine derivatives, their preparation and use in pharmaceutical compositions
DE3061205D1 (en) * 1979-06-16 1983-01-05 Beecham Group Plc Secondary amines, their preparation and use in pharmaceutical compositions
DE3062216D1 (en) * 1979-09-06 1983-04-07 Beecham Group Plc Cinnamic acid derivatives, their preparation, and pharmaceutical compositions containing them
EP0040000B1 (en) * 1980-05-08 1983-10-12 Beecham Group Plc Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions
EP0040915B1 (en) * 1980-05-22 1984-03-21 Beecham Group Plc Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions
CA1175851A (en) * 1980-09-26 1984-10-09 Beecham Group Limited Secondary amines
EP0052963B1 (en) * 1980-11-20 1985-02-20 Beecham Group Plc Secondary amines
EP0066351B1 (en) * 1981-03-06 1985-06-26 Beecham Group Plc Arylethanol amine derivatives, their preparation and use in pharmaceutical compositions
EP0061907B1 (en) * 1981-03-31 1984-08-01 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
EP0063004A1 (en) * 1981-04-09 1982-10-20 Beecham Group Plc Secondary amines, processes for their preparation, and pharmaceutical compositions containing them
EP0068669A1 (en) * 1981-06-20 1983-01-05 Beecham Group Plc Secondary phenylethanol amines, processes for their preparation and their pharmaceutical application
DE3267406D1 (en) * 1981-07-11 1985-12-19 Beecham Group Plc Secondary phenyl ethanol amines and their pharmaceutical use
FR2516512A1 (fr) * 1981-11-19 1983-05-20 Corbiere Jerome Nouveaux derives pyridoindoliques, leur procede de preparation et les compositions pharmaceutiques en contenant
IE54220B1 (en) * 1981-12-23 1989-07-19 Ici Plc Phenol esters
EP0089154A3 (en) * 1982-03-12 1984-08-08 Beecham Group Plc Ethanolamine derivatives, their preparation and use in pharmaceutical compositions
FR2523965B1 (fr) * 1982-03-24 1985-09-27 Bellon Labor Sa Roger (benzimidazolyl-1)-1, n-((hydroxy-4 methoxy-3 phenyl)-2 hydroxy-2 ethyl) amino-3 butane et ses sels a activite b-adrenergique, leurs applications therapeutiques, et procede pour les preparer
EP0091749A3 (en) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
DE3360426D1 (en) * 1982-04-08 1985-08-29 Beecham Group Plc N-substituted derivatives of ethanol amine
CA1219865A (en) * 1982-05-14 1987-03-31 Leo Alig Aziridine phenethanolamine derivatives
DE3368258D1 (en) * 1982-07-16 1987-01-22 Beecham Group Plc 2-aminoethyl ether derivatives, processes for their preparation and pharmaceutical compositions containing them
EP0102213A1 (en) * 1982-08-21 1984-03-07 Beecham Group Plc Ethanolamine derivatives, pharmaceutical compositions containing them, and processes for preparing them
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
US5166218A (en) * 1983-10-19 1992-11-24 Hoffmann-La Roche Inc. Phenoxypropanolamines and pharmaceutical compositions thereof
CA1262729A (en) * 1983-10-19 1989-11-07 Leo Alig Phenoxypropanolamines
GB8419797D0 (en) * 1984-08-03 1984-09-05 Beecham Group Plc Compounds
GB8507942D0 (en) * 1985-03-27 1985-05-01 Beecham Group Plc Compounds
IL79323A (en) * 1985-07-10 1990-03-19 Sanofi Sa Phenylethanolaminotetralines,their preparation and pharmaceutical compositions containing them
GB8519154D0 (en) * 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
GB8714901D0 (en) * 1986-07-23 1987-07-29 Ici Plc Amide derivatives
DE3866984D1 (en) * 1987-07-21 1992-01-30 Hoffmann La Roche Phenoxypropanolamine.
DE3800096A1 (de) * 1988-01-05 1989-07-13 Bayer Ag Verwendung von benzimidazolderivaten als leistungsfoerderer
GB8801306D0 (en) * 1988-01-21 1988-02-17 Ici Plc Chemical compounds
NZ229376A (en) * 1988-06-03 1991-07-26 Lilly Co Eli Aryloxysubstituted propanolamines and pharmaceutical compositions
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
IT1226726B (it) * 1988-07-29 1991-02-05 Zambon Spa Composti attivi come inibitori della biosintesi del colesterolo.
US5254595A (en) * 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
GB8905336D0 (en) * 1989-03-08 1989-04-19 Ici Plc Chemical compounds
DE4040186A1 (de) * 1989-12-20 1991-06-27 Hoechst Ag Hypoglykaemisch aktive propandiolaminderivate mit insulin-aehnlicher wirkung und deren verwendung, neue propandiolaminderivate, diese substanzen enthaltende pharmazeutische zubereitungen und ihre verwendung zur behandlung von krankheiten
IE65511B1 (en) * 1989-12-29 1995-11-01 Sanofi Sa New phenylethanolaminomethyltetralins
US5360811A (en) * 1990-03-13 1994-11-01 Hoechst-Roussel Pharmaceuticals Incorporated 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
US5061727A (en) * 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
EP0499755A1 (fr) * 1991-02-18 1992-08-26 MIDY S.p.A. Nouvelles phényléthanolaminotétralines, procédé pour leur préparation, intermédiaires dans ce procédé et compositions pharmaceutiques les contenant
GB9107827D0 (en) * 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
GB9207964D0 (en) * 1992-04-10 1992-05-27 Ici Plc Chemical compounds
GB9209076D0 (en) * 1992-04-27 1992-06-10 Ici Plc Chemical compounds
GB9215844D0 (en) * 1992-07-25 1992-09-09 Smithkline Beecham Plc Novel compounds
WO1994003425A2 (en) * 1992-07-31 1994-02-17 Syntex (U.S.A.) Inc. Carbostyril derivatives for the treatment of arrhythmia
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US5321036A (en) * 1993-02-10 1994-06-14 Bristol-Myers Squibb Company Thiazole and oxazole-based β3 adrenergic receptor agonists
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
EP0627407A1 (fr) * 1993-05-28 1994-12-07 MIDY S.p.A. Acide (7S)-7-[(2R)-2(3-chlorophényl)-2-hydroxyéthylamino]-5,6,7,8-tétrahydronaphtalèn-2-yloxy acétique, ses sels pharmaceutiquement acceptables, à action agoniste bêta-3 adrénergique et compositions pharmaceutiques le contenant
CN1129443A (zh) * 1993-06-14 1996-08-21 美国辉瑞有限公司 仲胺用作治糖尿病和治肥胖病药物
GB9313574D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Medicaments
WO1995004047A1 (en) * 1993-07-31 1995-02-09 Smithkline Beecham Plc 2-benzoheterocyclyloxy or thiopropanolamine derivatives with adreno receptor agonist activity
IL110857A0 (en) * 1993-09-09 1994-11-28 Lilly Co Eli Cessation of tobacco use
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5541197A (en) * 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
CA2196193A1 (en) * 1994-07-29 1996-02-15 Lee James Beeley Aryloxy and arylthiopropanolamine derivatives useful as beta 3-adrenoreceptor agonists and antagonists of the beta 1 and beta 2-adrenoreceptors and pharmaceutical composition thereof
US5726165A (en) * 1994-07-29 1998-03-10 Smithkline Beecham P.L.C. Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
ATE215369T1 (de) * 1996-09-05 2002-04-15 Lilly Co Eli Carbazolanaloge als selektive beta3-adrenergische agonisten
WO2004036435A1 (ja) 2002-10-15 2004-04-29 Matsushita Electric Industrial Co., Ltd. デジタルアイテムの管理情報の管理システム
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
US7858121B2 (en) 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl

Also Published As

Publication number Publication date
ID17182A (id) 1997-12-04
DE69711519D1 (de) 2002-05-08
EP0827746B1 (en) 2002-04-03
US20020165234A1 (en) 2002-11-07
ES2171839T3 (es) 2002-09-16
ATE215369T1 (de) 2002-04-15
MY132626A (en) 2007-10-31
AR009518A1 (es) 2000-04-26
EP0827746A1 (en) 1998-03-11
JP4212117B2 (ja) 2009-01-21
US20050043337A1 (en) 2005-02-24
US6413991B1 (en) 2002-07-02
JP2002513387A (ja) 2002-05-08
US6686372B2 (en) 2004-02-03
US7041684B2 (en) 2006-05-09
CO4910132A1 (es) 2000-04-24
US6140352A (en) 2000-10-31
AU4094197A (en) 1998-03-26
AR009519A1 (es) 2000-04-26
PE109398A1 (es) 1999-01-15
WO1998009625A1 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
DE69711519T2 (de) Carbazolanaloge als selektive beta3-adrenergische Agonisten
AU715175B2 (en) Selective B3 adrenergic agonists
DE69403823T2 (de) Substituierte Phenylsulfonamine als selektive B3-Agonisten zur Behandlung von Diabetes und Fettleibigkeit
US6265581B1 (en) Selective β3 adrenergic agonists
DE60211199T2 (de) 3-substituierte oxindol-beta-3-agonisten
DE60225174T2 (de) Beta-3 adrenergische agonisten
EP1228059B1 (de) Neue cyclopropane als cgrp-antagonisten, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US6617347B1 (en) Selective β3 adrenergic agonists
DE69614057T2 (de) Selektive Beta3-adrenergische Agonisten
SK285373B6 (sk) 2-(3,5-bis-Trifluórmetylfenyl)-N-metyl-N-(6-morfolin-4-yl-4-o- tolylpyridin-3-yl)izobutyramid, spôsob jeho prípravy a použitie a liečivo obsahujúce túto zlúčeninu
CA2506735A1 (en) Indole derivatives as somatostatin agonists or antagonists
US6232337B1 (en) Selective β3 adrenergic agonists
CA2236269C (en) Selective .beta.3 adrenergic agonists
HK1009389A (en) Carbazole analogues as selective b3 adrenergic agonists
HK1023768A (en) Selective beta 3 adrenergic agonists
MXPA98002097A (en) Beta3 selecti adrenergic agonists
AU3132700A (en) Slective beta3 adrenergic agonists
IL134420A (en) AMINE INTERMEDIATES USEFUL FOR THE PREPARATION OF β3 ADRENERGIC RECEPTOR AGONISTS

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN